UNLIMITED TURBO SHORT - NOVO-NORDISK B | Market Closed - Euronext Paris 17:30:01 24/05/2024 BST | ||
| 2.74 EUR | +3.01% |
|
| Current month | -13.51% | ||
| 1 month | -20.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 2.85 | +7.14% |
| 23/05/24 | 2.66 | -9.83% |
| 22/05/24 | 2.95 | +3.69% |
| 21/05/24 | 2.845 | -12.46% |
| 17/05/24 | 3.25 | +5.18% |
Real-time Euronext Paris
Last update May 24, 2024 at 05:30 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| TS4NB | |
| ISIN | NLBNPNL2O292 |
| Date issued | 26/02/2024 |
| Strike | 1,120 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.465 € |
|---|---|
| Lowest since issue | 2.66 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
928.8
DKK
Average target price
909.2
DKK
Spread / Average Target
-2.11%
- Stock Market
- Certificates
- TS4NB Certificat
